Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: A randomized trial

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 426-433

  Wang, Y ^a   Fu, H X ^a   Liu, D H ^a   Xu, L P ^a   Zhang, X H ^a   Chang, Y J ^a   Chen, Y H ^a   Wang, F R ^a   Sun, Y Q ^a   Tang, F F ^a   Liu, K Y ^a   Huang, X J ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

antithymocyte globulin; HLA mismatched; transplantation

Indexed keywords

BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; SEMUSTINE; THYMOCYTE ANTIBODY; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; EPSTEIN BARR VIRUS; EX VIVO STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INCIDENCE; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; OPEN STUDY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; VIRUS REACTIVATION; ADVERSE EFFECTS; ALLELE; CHEMISTRY; CYTOMEGALOVIRUS; DONOR; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; METABOLISM; POSTOPERATIVE COMPLICATION; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84904243580     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.191     Document Type: Article

References (24)

1. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukaemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-265.
2. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942-2947.
3. Duggan P, Booth K, Chaudhry A, Stewart D, Stewart D, Ruether JD et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002; 30: 681-686.
4. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol 2003; 31: 1026-1030.
5. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Haploidentical allogeneic hematopoietic stem cell transplantation for the treatment of refractory/relapsed acute leukemia. Chin J Hematol 2012; 33: 916-920.
6. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute myeloid leukemia in first complete remission. Blood 2012; 119: 5584-5590.
7. Yan CH, Liu DH, Xu LP, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse and improve survival of patients with standard-risk acute leukemia after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256-3262.
8. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414-417.
9. Sullivan KM. Grfte-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, MA, USA, 1999, pp 515-536.
10. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
11. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis[J]. Biol Blood Marrow Transplant 2007; 13: 299-306.
12. Christopher N, Zhang M-J, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide[J]. Biol Blood Marrow Transplant 2008; 14: 993-1003.
13. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476.
14. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122-127.
15. Schleuning M, Gunther W, Tischer J, Ledderose G, Kolb HJ. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243-250.
16. Portier DA, Sabo RT, Roberts CH, Fletcher DS, Meier J, Clark WB et al. Anti-thy-mocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transplant 2012; 47: 1513-1519.
17. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118: 6006-6017.
18. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/ haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012; 47: 1099-1104.
19. Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012; 47: 1507-1512.
20. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in-vitro T-cell-depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978-985.
21. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS et al. Equivalence of two effective graft-versus-host disease prophylaxis regimens: results of a prospective double blind randomized trial. Biol Blood Marrow Transplant 2000; 6: 254-261.
22. Duval M, Pédron B, Rohrlich P, Legrand F, Faye A, Lescoeur B et al. Immune reconstitution after haematopoietic transplantation with two different doses of pre-graft antithymocyte globulin. Bone Marrow Transplant 2002; 30: 421-426.
23. Ramsay NKC, Kersey JH, Robinson LL, McGlave PB, Woods WG, Krivit W et al. A randomized study of the prevention of acute graft versus host disease. N Engl J Med 1982; 306: 392-397.
24. Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000; 26: 251-255.